Abstract | BACKGROUND: METHODS: Tissue microarrays of 88 surgically resected IBC tumors were stained immunohistochemically for EZH2, and the authors evaluated the association of EZH2 expression status with clinicopathologic factors and clinical outcome. RESULTS: The median follow-up for the entire cohort was 45.7 months, and the 5-year overall survival (OS) rate was 45%. EZH2 was expressed frequently in IBC tumors (75.7%) and was associated significantly with unfavorable prognostic factors, such as higher tumor grade, negative estrogen receptor status, and triple-negative status (ie, negative for the estrogen, progesterone, and human epidermal growth factor 2 receptors). Univariate survival analysis indicated that patients who had EZH2-positive IBC had a significantly lower 5-year OS rate than patients who had EZH2-negative IBC (P = .01). In multivariate analysis, only positive EZH2 status remained an independent predictor of worse OS. CONCLUSIONS: EZH2 was expressed frequently in IBC tumors. The current results indicated that EZH2 expression status may be used to identify a subset of patients with IBC who have a relatively worse prognosis. Targeting EZH2 also may provide a novel strategy for improving the clinical outcome of patients with IBC.
|
Authors | Yun Gong, Lei Huo, Ping Liu, Nour Sneige, Xiaoping Sun, Naoto T Ueno, Anthony Lucci, Thomas A Buchholz, Vicente Valero, Massimo Cristofanilli |
Journal | Cancer
(Cancer)
Vol. 117
Issue 24
Pg. 5476-84
(Dec 15 2011)
ISSN: 1097-0142 [Electronic] United States |
PMID | 21713757
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 American Cancer Society. |
Chemical References |
- DNA-Binding Proteins
- Polycomb-Group Proteins
- Repressor Proteins
- Transcription Factors
- EZH2 protein, human
- Enhancer of Zeste Homolog 2 Protein
- Polycomb Repressive Complex 2
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Chemotherapy, Adjuvant
- Cohort Studies
- DNA-Binding Proteins
(biosynthesis)
- Enhancer of Zeste Homolog 2 Protein
- Female
- Humans
- Immunohistochemistry
- Inflammatory Breast Neoplasms
(drug therapy, metabolism, pathology, surgery)
- Mastectomy
- Microarray Analysis
- Middle Aged
- Neoadjuvant Therapy
- Polycomb Repressive Complex 2
- Polycomb-Group Proteins
- Repressor Proteins
(biosynthesis)
- Retrospective Studies
- Transcription Factors
(biosynthesis)
- Treatment Outcome
- Young Adult
|